What the FDA labels say about taking them together
Darunavir and dihydroergotamine
Darunavir's FDA label of August 29, 2025 names dihydroergotamine in its contraindications section; the dihydroergotamine labels PlainMeds reads (4) do not name darunavir. The darunavir label: “Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.”
Check it at the source: the darunavir FDA label on DailyMed (effective August 29, 2025, Janssen Products LP); the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals).
What does the darunavir label say about dihydroergotamine?
Darunavir label, contraindicationsAlpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product:
Darunavir label, drug interactionsConcomitant Drug Class Drug Name Examples: e.g. dihydroergotamine, ergotamine, methylergonovine; Effect on Concentration of Darunavir Or Concomitant Drug: ↑ ergot derivatives; Clinical Comment: Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Source: FDA drug label (PREZISTA), Janssen Products LP, effective August 29, 2025 (SPL set 814301f9-c990-46a5-b481-2879a521a16f), via openFDA; the full label on DailyMed
What does the dihydroergotamine label say about darunavir?
Dihydroergotamine's label (effective March 6, 2025) and its 3 other brand-application labels do not name darunavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Darunavir | Dihydroergotamine | |
|---|---|---|
| Labeled for | HIV | Migraine |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.16 per tablet 600 mg tablet | $29.44 per mL 4 mg/mL nasal spray |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once